Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03996369 · ClinicalTrials.gov registry record · Phase 3
Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis
A Phase 3 study, sponsored by Arena Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 354
- Enrollment target
NCT03996369 is a Phase 3 study that has completed, run by Arena Pharmaceuticals. The registered enrollment target is 354 participants.
The verdict
NCT03996369, a Phase 3 study, has completed, sponsored by Arena Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 354 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy of etrasimod on clinical remission in participants with moderately to severely active ulcerative colitis (UC).
Interventions
- DRUG Placebo
- DRUG Etrasimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 354 participants |
| Start Date | 2020-09-15 |
| Est. Completion | 2021-12-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03996369
The ClinicalTrials.gov registry entry for NCT03996369 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 354 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arena Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03996369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03996369 about?
NCT03996369 is a clinical study titled "Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis". The purpose of this study is to assess the efficacy of etrasimod on clinical remission in participants with moderately to severely active ulcerative colitis (UC).
What is the current status of trial NCT03996369?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 354 participants. The study started on 2020-09-15. Estimated completion is 2021-12-07.
What interventions are being tested in trial NCT03996369?
The interventions under investigation include: Placebo (DRUG), Etrasimod (DRUG).
Who is sponsoring clinical trial NCT03996369?
This trial is sponsored by Arena Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.